SCHEMBL30004144

SCHEMBL30004144

CC(=O)c1cc(F)ccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
GRM5 P41594 3/20 0.40
MAPK14 Q16539 1/20 0.40
KDM4E B2RXH2 3/20 0.39
MAPT P10636 2/20 0.39
KDM6B O15054 1/20 0.39
TET3 O43151 1/20 0.39
KDM4A O75164 1/20 0.39
BBOX1 O75936 1/20 0.39
KDM5A P29375 1/20 0.39
KDM5C P41229 1/20 0.39
ASPH Q12797 1/20 0.39
KDM4D Q6B0I6 1/20 0.39
TET2 Q6N021 1/20 0.39
ALKBH5 Q6P6C2 1/20 0.39
KDM7A Q6ZMT4 1/20 0.39
KDM8 Q8N371 1/20 0.39
TET1 Q8NFU7 1/20 0.39
EGLN2 Q96KS0 1/20 0.39
FTO Q9C0B1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1612977 1.00 ALDH1A1 (0.50) ALDH1A1GRM5MAPK14KDM4EMAPT
SCHEMBL231979 0.81 KDM4E (0.61) ALDH1A1GRM5KDM4EMAPTKDM6B
SCHEMBL29954072 0.81 KDM4E (0.61) ALDH1A1GRM5KDM4EMAPTKDM6B
SCHEMBL30668214 0.79 ADORA3 (0.45) ALDH1A1GRM5KDM4EMAPTKDM6B
SCHEMBL2275018 0.79 KDM4E (0.59) ALDH1A1GRM5KDM4EMAPTKDM6B
SCHEMBL23874595 0.79 GRM5 (0.43) ALDH1A1GRM5KDM4EMAPTKDM6B
SCHEMBL7692385 0.79 ADORA3 (0.45) ALDH1A1GRM5KDM4EMAPTKDM6B
SCHEMBL2305000 0.79 ALDH1A1 (0.50) ALDH1A1GRM5KDM4EMAPTKDM6B
SCHEMBL30945316 0.79 ALDH1A1 (0.50) ALDH1A1GRM5KDM4EMAPTKDM6B
SCHEMBL9772819 0.78 GRM5 (0.40) ALDH1A1GRM5KDM4EMAPTKDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) 2024-08-29 US disclosed
US-20240279227-A1 FUSED HETEROCYCLIC DERIVATIVES JANSSEN BIOTECH, INC. 2024-08-22 US disclosed
CN-117881661-A Condensed heterocyclic derivative 杨森科学爱尔兰无限公司 2024-04-12 CN disclosed
EP-4347036-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2024-04-10 EP disclosed
EP-4347590-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2024-04-10 EP disclosed
CN-117715909-A Condensed heterocyclic derivative 杨森科学爱尔兰无限公司 2024-03-15 CN disclosed
WO-2022253255-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2022-12-08 WO disclosed
WO-2022253259-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2022-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES HAVCR2, HCCS, GOT2 ALDH1A1 2000/4885GRM5 3939/4885MAPK14 2681/4885
US-20240279227-A1 FUSED HETEROCYCLIC DERIVATIVES HAVCR2, HCCS, GOT2 ALDH1A1 2000/4885GRM5 3939/4885MAPK14 2681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.